365 related articles for article (PubMed ID: 24521249)
1. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
Moreau P
Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
[TBL] [Abstract][Full Text] [Related]
2. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
Stewart AK
Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
[TBL] [Abstract][Full Text] [Related]
4. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak AJ
Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib in multiple myeloma.
Andreu-Vieyra C; Berenson JR
Expert Opin Biol Ther; 2014 Nov; 14(11):1685-99. PubMed ID: 25170966
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors in the treatment of multiple myeloma.
McBride A; Ryan PY
Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.
Landgren O; Sonneveld P; Jakubowiak A; Mohty M; Iskander KS; Mezzi K; Siegel DS
Leukemia; 2019 Sep; 33(9):2127-2143. PubMed ID: 31341235
[TBL] [Abstract][Full Text] [Related]
15. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
Pautasso C; Bringhen S; Cerrato C; Magarotto V; Palumbo A
Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1371-9. PubMed ID: 23834482
[TBL] [Abstract][Full Text] [Related]
17. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
18. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
Shah JJ
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
[TBL] [Abstract][Full Text] [Related]
19. Sequential or combination therapy for multiple myeloma.
Nooka A; Lonial S
Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
[TBL] [Abstract][Full Text] [Related]
20. Future agents and treatment directions in multiple myeloma.
Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]